Tufts R&D Cost Estimate Puts Cash Outlay At $403 Mil. Per NCE
Executive Summary
The cash outlay required to complete development of a new chemical entity has increased to an average of more than $400 mil., the Tufts Center for the Study of Drug Development says
You may also be interested in...
Biologic R&D Cash Outlays Exceed Those For Small Molecules – Tufts Study
Companies' out-of-pocket expenses to bring a biopharmaceutical to market exceed those for new chemical entities, a Tufts Center for the Study of Drug Development analysis found
Biologic R&D Cash Outlays Exceed Those For Small Molecules – Tufts Study
Companies' out-of-pocket expenses to bring a biopharmaceutical to market exceed those for new chemical entities, a Tufts Center for the Study of Drug Development analysis found
Novartis E-Trial Program Will Help Reduce Clinical Trial Personnel By 25%
Novartis' productivity improvements through electronic data capture will result in an approximate one-quarter reduction in data management personnel and clinical research associates by January 2004